Incidence of Pathologic Nodal Disease in Clinically Node-Negative, Microinvasive or T1a Breast Cancers

Background Axillary staging in early-stage breast cancer can impact adjuvant treatment options but also has associated morbidity. The incidence of pathologic nodal positivity (pN+) in patients with microinvasive or T1a disease is poorly characterized and the value of sentinel node biopsy remains con...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of surgical oncology 2024-12, Vol.31 (13), p.8821-8828
Hauptverfasser:	Dey, Pranam, Kc, Madhav, Proussaloglou, Ellie M., Khubchandani, Jasmine A., Kim, Leah, Zanieski, Gregory, Park, Tristen, Lynch, Melanie, Gillego, Alyssa, Valero, Monica, Schneider, Eric, Golshan, Mehra, Greenup, Rachel A., Berger, Elizabeth R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Axilla Biopsy Breast cancer Breast Neoplasms - epidemiology Breast Neoplasms - metabolism Breast Neoplasms - pathology Breast Neoplasms - surgery Breast Oncology Carcinoma, Ductal, Breast - epidemiology Carcinoma, Ductal, Breast - metabolism Carcinoma, Ductal, Breast - pathology Carcinoma, Ductal, Breast - surgery Carcinoma, Lobular - epidemiology Carcinoma, Lobular - metabolism Carcinoma, Lobular - pathology Carcinoma, Lobular - surgery Comorbidity ErbB-2 protein Female Follow-Up Studies Histology Humans Incidence Invasiveness Lymph Nodes - pathology Lymph Nodes - surgery Lymphatic Metastasis Medicine Medicine & Public Health Middle Aged Morbidity Neoplasm Invasiveness Neoplasm Staging Oncology Patients Prognosis Receptor, ErbB-2 - metabolism Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism Sentinel Lymph Node Biopsy Surgery Surgical Oncology Triple Negative Breast Neoplasms - epidemiology Triple Negative Breast Neoplasms - metabolism Triple Negative Breast Neoplasms - pathology Triple Negative Breast Neoplasms - surgery Womens health
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!